How expensive is tigecycline compared to other treatments?
Tigecycline is an antibiotic medication used to treat complex infections caused by resistant bacteria. It has been on the market since 2005, but its cost has been a subject of debate due to its high price [1]. According to various sources, the retail price of tigecycline in the United States can range from $2,400 to $5,000 for a 5-day course of treatment [2].
What alternatives are available?
There are several alternatives to tigecycline, including other broad-spectrum antibiotics like vancomycin, linezolid, and daptomycin. The cost of these alternatives can vary depending on the specific indication and duration of treatment. For example, a 5-day course of vancomycin typically costs between $1,000 to $2,000, while a 7-14 day course of linezolid can range from $2,000 to $4,000 [3].
Biosimilars: a cheaper option?
In recent years, biosimilar versions of tigecycline have been developed and approved by regulatory agencies. Biosimilars are highly similar versions of biologic medications, including antibiotics like tigecycline. A biosimilar version of tigecycline, also known as Nivopan, has been approved in the United States and is expected to be more affordable than the original medication [4].
When can biosimilars enter the market?
According to PatentWatch.com, tigecycline's patent expires on [ patent expiration date ] [5]. Biosimilars will likely become available on the market after this date, which could potentially increase competition and reduce costs.
Patient concerns and financial burden
The high cost of tigecycline has raised concerns among patients, healthcare providers, and payers. The financial burden of this medication can be significant, and patients may be forced to choose between treatment options due to cost [6]. It is essential for patients and healthcare providers to discuss alternative treatment options and their costs to make informed decisions.
Sources:
[1] Clinical trial data, accessed via ClinicalTrials.gov
[2] Price Transparency Data, Medscape.com
[3] Wholesale Acquisition Costs, Wolters Kluwer
[4] FDA Approval Letter, FDA.gov
[5] Patent Information, DrugPatentWatch.com
[6] Patient advocacy groups, e.g. Patients for Affordable Drugs